<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aeolus Pharmaceuticl — News on 6ix</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl</link>
<description>Latest news and press releases for Aeolus Pharmaceuticl on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 23 Mar 2018 20:30:36 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aeolus-pharmaceuticl" rel="self" type="application/rss+xml" />
<item>
<title>Aeolus Announces Commencement of Assignment for the Benefit of Creditors</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-commencement-of-assignment-for-the-benefit-of-creditors</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-commencement-of-assignment-for-the-benefit-of-creditors</guid>
<pubDate>Fri, 23 Mar 2018 20:30:36 GMT</pubDate>
<description>Aeolus Announces Commencement of Assignment for the Benefit of Creditors.</description>
</item>
<item>
<title>Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-presentation-of-pharmacometric-analysis-confirming-statistically-significant-improvement-in-survival-6-months-after-exposure-to-lethal-thoracic-radiation-following-treatment-with-aeol-10150</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-presentation-of-pharmacometric-analysis-confirming-statistically-significant-improvement-in-survival-6-months-after-exposure-to-lethal-thoracic-radiation-following-treatment-with-aeol-10150</guid>
<pubDate>Tue, 26 Sep 2017 12:00:30 GMT</pubDate>
<description>Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150.</description>
</item>
<item>
<title>Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-presentation-of-pharmacometric-analysis-of-data-establishing-optimal-dose-schedule-of-aeol-10150-for-treatment-of-lung-radiation-damage</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-presentation-of-pharmacometric-analysis-of-data-establishing-optimal-dose-schedule-of-aeol-10150-for-treatment-of-lung-radiation-damage</guid>
<pubDate>Fri, 22 Sep 2017 12:00:38 GMT</pubDate>
<description>Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage.</description>
</item>
<item>
<title>Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats </title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-publication-of-data-demonstrating-that-adding-aeol-10150-to-standard-therapy-after-nerve-agent-exposure-improves-survival-and-reduces-brain-damage-and-nerve-inflammation-in-rats</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-publication-of-data-demonstrating-that-adding-aeol-10150-to-standard-therapy-after-nerve-agent-exposure-improves-survival-and-reduces-brain-damage-and-nerve-inflammation-in-rats</guid>
<pubDate>Wed, 20 Sep 2017 12:01:44 GMT</pubDate>
<description>Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats.</description>
</item>
<item>
<title>AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-aeol-10150-is-safe-and-well-tolerated-in-phase-1-study-in-healthy-subjects</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-aeol-10150-is-safe-and-well-tolerated-in-phase-1-study-in-healthy-subjects</guid>
<pubDate>Mon, 18 Sep 2017 12:01:08 GMT</pubDate>
<description>AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects.</description>
</item>
<item>
<title>Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-third-quarter-financial-results-for-fiscal-year-2017</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-third-quarter-financial-results-for-fiscal-year-2017</guid>
<pubDate>Mon, 14 Aug 2017 22:11:34 GMT</pubDate>
<description>Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017.</description>
</item>
<item>
<title>Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-fda-fast-track-designation-granted-to-aeol-10150-for-treatment-of-patients-with-lung-acute-radiation-syndrome-following-a-radiologial-or-nuclear-event</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-fda-fast-track-designation-granted-to-aeol-10150-for-treatment-of-patients-with-lung-acute-radiation-syndrome-following-a-radiologial-or-nuclear-event</guid>
<pubDate>Thu, 08 Jun 2017 14:44:12 GMT</pubDate>
<description>Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event.</description>
</item>
<item>
<title>Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-second-quarter-financial-results-for-fiscal-year-2017</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-second-quarter-financial-results-for-fiscal-year-2017</guid>
<pubDate>Mon, 15 May 2017 21:10:43 GMT</pubDate>
<description>Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017.</description>
</item>
<item>
<title>Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-receives-barda-decision-regarding-additional-options-for-lung-ars-development-contract-files-response-to-assertions-made-by-barda-in-the-notification</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-receives-barda-decision-regarding-additional-options-for-lung-ars-development-contract-files-response-to-assertions-made-by-barda-in-the-notification</guid>
<pubDate>Thu, 23 Mar 2017 12:12:44 GMT</pubDate>
<description>Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification.</description>
</item>
<item>
<title>AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeol-20415-protects-lungs-against-infection-in-animal-model-of-cystic-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeol-20415-protects-lungs-against-infection-in-animal-model-of-cystic-fibrosis</guid>
<pubDate>Wed, 15 Mar 2017 13:22:44 GMT</pubDate>
<description>AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis.</description>
</item>
<item>
<title>Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-initiates-phase-1-study-of-aeol-10150-in-healthy-normal-volunteers</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-initiates-phase-1-study-of-aeol-10150-in-healthy-normal-volunteers</guid>
<pubDate>Wed, 22 Feb 2017 20:20:11 GMT</pubDate>
<description>Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers.</description>
</item>
<item>
<title>Aeolus Announces Fiscal Year 2016 Financial Results</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-fiscal-year-2016-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-fiscal-year-2016-financial-results</guid>
<pubDate>Wed, 21 Dec 2016 13:12:46 GMT</pubDate>
<description>Aeolus Announces Fiscal Year 2016 Financial Results.</description>
</item>
<item>
<title>Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-publication-of-additional-data-demonstrating-efficacy-of-aeol-10150-in-sulfur-mustard-exposure-in-journal-toxicological-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-publication-of-additional-data-demonstrating-efficacy-of-aeol-10150-in-sulfur-mustard-exposure-in-journal-toxicological-sciences</guid>
<pubDate>Mon, 19 Sep 2016 17:07:43 GMT</pubDate>
<description>Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences".</description>
</item>
<item>
<title>Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-positive-data-confirming-efficacy-of-aeol-10150-as-a-medical-countermeasure-against-sulfur-mustard-gas</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-positive-data-confirming-efficacy-of-aeol-10150-as-a-medical-countermeasure-against-sulfur-mustard-gas</guid>
<pubDate>Tue, 06 Sep 2016 12:40:12 GMT</pubDate>
<description>Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas.</description>
</item>
<item>
<title>Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-pharmaceuticals-to-present-at-aegis-growth-conference-on-september-22-2016</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-pharmaceuticals-to-present-at-aegis-growth-conference-on-september-22-2016</guid>
<pubDate>Wed, 31 Aug 2016 13:25:42 GMT</pubDate>
<description>Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016.</description>
</item>
<item>
<title>Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-third-quarter-fiscal-year-2016-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-third-quarter-fiscal-year-2016-financial-results</guid>
<pubDate>Mon, 15 Aug 2016 20:38:11 GMT</pubDate>
<description>Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results.</description>
</item>
<item>
<title>StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/stocknewsnowcom-publishes-new-snnlive-video-interview-with-aeolus-pharmaceuticals-inc-discussing-clinical-development-and-milestones-for-2016-2017</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/stocknewsnowcom-publishes-new-snnlive-video-interview-with-aeolus-pharmaceuticals-inc-discussing-clinical-development-and-milestones-for-2016-2017</guid>
<pubDate>Thu, 07 Jul 2016 12:11:12 GMT</pubDate>
<description>StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017.</description>
</item>
<item>
<title>Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-pharmaceuticals-to-present-at-ld-micro-invitational-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-pharmaceuticals-to-present-at-ld-micro-invitational-conference</guid>
<pubDate>Tue, 24 May 2016 23:55:30 GMT</pubDate>
<description>Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference.</description>
</item>
<item>
<title>European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/european-patent-issued-and-patent-allowed-in-japan-for-aeolus-parkinsons-disease-compound-aeol-11114</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/european-patent-issued-and-patent-allowed-in-japan-for-aeolus-parkinsons-disease-compound-aeol-11114</guid>
<pubDate>Mon, 18 Apr 2016 12:24:32 GMT</pubDate>
<description>European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114.</description>
</item>
<item>
<title>Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016</title>
<link>https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-removal-of-fda-clinical-hold-on-aeol-10150-initiation-of-phase-1-study-in-healthy-volunteers-planned-for-2nd-quarter-2016</link>
<guid isPermaLink="true">https://6ix.com/company/aeolus-pharmaceuticl/news/aeolus-announces-removal-of-fda-clinical-hold-on-aeol-10150-initiation-of-phase-1-study-in-healthy-volunteers-planned-for-2nd-quarter-2016</guid>
<pubDate>Mon, 22 Feb 2016 13:28:00 GMT</pubDate>
<description>Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016.</description>
</item>
</channel>
</rss>